Rigel Pharmaceuticals (RIGL) Interest Coverage Ratio (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Interest Coverage Ratio of 5.06 for Q1 2026, up 507.32% year-over-year from 0.83 in Q1 2025, and up 34.68% quarter-over-quarter from 3.75 in Q4 2025.
Rigel Pharmaceuticals (RIGL) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Interest Coverage Ratio history runs 17 years deep, the most recent figure standing at 5.06 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 507.32% year-over-year to 5.06; the TTM figure through Mar 2026 stood at 52.99 (up 1750.91% YoY), while the FY2025 annual figure was 2.69, up 3556.46% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 5.06, up from 3.75 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 6.34 in Q4 2024, with the low at 8.06 in Q1 2023.
- The 5-year median for Interest Coverage Ratio is 0.03 (2024), against an average of 0.07.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio sank 268.43% in 2022, then surged 15662.99% in 2025.
- Rigel Pharmaceuticals' Interest Coverage Ratio stood at 0.5 in 2022, then soared by 245.05% to 0.73 in 2023, then soared by 772.64% to 6.34 in 2024, then plunged by 40.82% to 3.75 in 2025, then soared by 34.68% to 5.06 in 2026.
- Business Quant data shows RIGL's Interest Coverage Ratio at 5.06 in Q1 2026, 3.75 in Q4 2025, and 1.85 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 3.34 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.26 |
| Mar 31, 2026 | 5.06 |
| Dec 31, 2025 | 3.75 |
| Sep 30, 2025 | 1.85 |
| Jun 30, 2025 | 3.98 |
| Mar 31, 2025 | 0.83 |
| Dec 31, 2024 | 6.34 |
| Sep 30, 2024 | 0.79 |
| Jun 30, 2024 | 0.03 |
| Mar 31, 2024 | -0.39 |
| Dec 31, 2023 | 0.73 |
| Sep 30, 2023 | -2.35 |
| Jun 30, 2023 | -2.83 |
| Mar 31, 2023 | -8.06 |
| Dec 31, 2022 | -0.50 |
| Sep 30, 2022 | -5.25 |
| Jun 30, 2022 | -2.11 |
| Mar 31, 2022 | -3.00 |
| Dec 31, 2021 | -16.49 |
| Sep 30, 2021 | -1.42 |